Protective effect of green tea against prostate cancer: A case-control study in southeast China

被引:268
作者
Jian, L
Xie, LP
Lee, AH
Binns, CW
机构
[1] Curtin Univ Technol, Sch Publ Hlth, Perth, WA 6845, Australia
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou 310027, Peoples R China
关键词
case-control study; green tea; prostate cancer; risk factors;
D O I
10.1002/ijc.11550
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To investigate whether green tea consumption has an etiological association with prostate cancer, a case-control study was conducted in Hangzhou, southeast China during 2001-2002. The cases were 130 incident patients with histologically confirmed adenocarcinoma of the prostate. The controls were 274 hospital inpatients without prostate cancer or any other malignant diseases, and matched to the age of cases. Information on duration, quantity and frequency of usual tea consumption, as well as the number of new batches brewed per day, were collected by face-to-face interview using a structured questionnaire. The risk of prostate cancer for tea consumption was assessed using multivariate logistic regression adjusting for age, locality, education, income, body mass index, physical activity, alcohol consumption, tobacco smoking, total fat intake, marital status, age at marriage, number of children, history of vasectomy and family history of prostate cancer. Among the cases, 55.4% were tea drinkers compared to 79.9% for the controls. Almost all the tea consumed was green tea. The prostate cancer risk declined with increasing frequency, duration and quantity of green tea consumption. The adjusted odds ratio (OR), relative to non-tea drinkers, were 0.28 (95% Cl = 0.17-0.47) for tea drinking, 0.12 (95% Cl = 0.06-0.26) for drinking tea over 40 years, 0.09 (9S% Cl = 0.04-0.21) for those consuming more than 1.5 kg of tea leaves yearly, and 0.27 (9S% Cl = 0.15-0.48) for those drinking more than 3 cups (I litre) daily. The dose response relationships were also significant, suggesting that green tea is protective against prostate cancer. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 48 条
  • [21] 3.0.CO
  • [22] 2-2
  • [23] Ji BT, 1997, INT J CANCER, V70, P255, DOI 10.1002/(SICI)1097-0215(19970127)70:3&lt
  • [24] 255::AID-IJC1&gt
  • [25] 3.0.CO
  • [26] 2-W
  • [27] Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer
    Kattan, MW
    Potters, L
    Blasko, JC
    Beyer, DC
    Fearn, P
    Cavanagh, W
    Leibel, S
    Scardino, PT
    [J]. UROLOGY, 2001, 58 (03) : 393 - 399
  • [28] Inhibition of Bcl-XL phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis
    Kazi, A
    Smith, DM
    Zhong, Q
    Dou, QP
    [J]. MOLECULAR PHARMACOLOGY, 2002, 62 (04) : 765 - 771
  • [29] Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China
    Lacey, JV
    Deng, J
    Dosemeci, M
    Gao, YT
    Mostofi, FK
    Sesterhenn, IA
    Xie, T
    Hsing, AW
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2001, 30 (02) : 341 - 349
  • [30] Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways
    Lin, JK
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2002, 25 (05) : 561 - 571